ライフサイエンスコーパス: paraneoplastic

1 ological disorders that were suspected to be paraneoplastic.

2 eurological presentation was suspected to be paraneoplastic.

3 d with the anti-Hu antibody is unequivocally paraneoplastic.

4 ast cancer, suggest that the disorder may be paraneoplastic.

5 predict specific cancers in the setting of a paraneoplastic acute transverse myelitis.

6 Sixty-three patients had paraneoplastic and 55 patients had nonparaneoplastic ata

7 eful in identifying a neurologic disorder as paraneoplastic and in finding the associated neoplasm.

8 s and toxicity of cancer therapy, associated paraneoplastic and physiologic responses to the tumor an

9 is is an autoimmune encephalitis that can be paraneoplastic and usually responds to treatment.

10 ed with tumours, but they are more often non-paraneoplastic, and antibody assays can help with diagno

11 ssociation with multiple antibodies, are not paraneoplastic, and are triggered by molecular mimicry o

12 may be pathogenetically important while the paraneoplastic antibodies alert the clinician to the pre

13 atients with PLE to determine the utility of paraneoplastic antibodies and other tests.

14 he combination of symptoms, MRI findings and paraneoplastic antibodies established the diagnosis of P

15 Paraneoplastic antibodies were negative, but VGKC-Ab ran

16 ymptoms, whose sera or CSF were examined for paraneoplastic antibodies, 79 had the presumptive diagno

17 ts with symptoms of LE, negative for typical paraneoplastic antibodies, in whom antibodies to voltage

18 by a potential structural stimulator in the paraneoplastic antigen Ma3 and Ma5 genes.

19 The Nova paraneoplastic antigens are neuron-specific RNA binding

20 nisms, and molecular characterization of the paraneoplastic antigens with implications as to their bi

21 n mouse tissues is distinct from that of the paraneoplastic autoantibodies PCA-1 (anti-Yo, marker of

22 Coexisting paraneoplastic autoantibodies, identified in 74% of pati

23 ts among 120,000 evaluated serologically for paraneoplastic autoantibodies.

24 Paraneoplastic autoantibody evaluation aided the diagnos

25 As in patients with idiopathic and paraneoplastic autoimmune autonomic neuropathy, the seve

26 nctive, corticosteroid-responsive, sometimes paraneoplastic autoimmune meningoencephalomyelitis.

27 a is commonly recognized in association with paraneoplastic autoimmune myasthenia gravis (MG), an IgG

28 seventh IgG neuronal autoantibody marker of paraneoplastic autoimmunity identifiable unambiguously b

29 ique scenarios occurring in 1 patient: PCA-1 paraneoplastic autoimmunity in a child, and a paraneopla

30 These data suggest a model of paraneoplastic autoimmunity in which cross-reactive immu

31 ave NMO-IgG among 85000 tested for suspected paraneoplastic autoimmunity.

32 ound in 19 of 46 patients with idiopathic or paraneoplastic autonomic neuropathy (41 percent), in 6 o

33 tor-binding antibodies and had idiopathic or paraneoplastic autonomic neuropathy.

34 orin-4 autoimmunity may in some cases have a paraneoplastic basis.

35 Although paraneoplastic blepharospasm is rare, it is an important

36 This is the only case of paraneoplastic blepharospasm that the authors know of th

37 ntrol patients with nystagmus, diplopia, and paraneoplastic brainstem dysfunction.

38 Over the same period, only one paraneoplastic case of limbic encephalitis was identifie

39 ted in some of the tumor types identified in paraneoplastic cases.

40 sive autoimmune CNS disorder, sometimes with paraneoplastic cause.

41 stem and to identify neurologic disorders as paraneoplastic caused by a specific tumor type.

42 he clinical and serological heterogeneity of paraneoplastic central nervous system disorders: Patient

43 Lambert-Eaton myasthenic syndrome (LEMS) and paraneoplastic cerebellar ataxia (PCA).

44 oplasmic antibody type 1 (PCA-1, or anti-Yo) paraneoplastic cerebellar ataxia has a poor prognosis, y

45 Twenty-five patients with paraneoplastic cerebellar degeneration (44%) had high ti

46 For example, patients with paraneoplastic cerebellar degeneration (PCD) appear to s

47 among the better described autoantibodies in paraneoplastic cerebellar degeneration (PCD) combined wi

48 Except for paraneoplastic cerebellar degeneration (PCD) in HL and d

49 Paraneoplastic cerebellar degeneration (PCD) is a disord

50 Paraneoplastic cerebellar degeneration (PCD) is believed

51 Patients with paraneoplastic cerebellar degeneration (PCD) offer the o

52 Patients with paraneoplastic cerebellar degeneration (PCD) provide an

53 was the cause of death of 65% HuAb positive paraneoplastic cerebellar degeneration and 10% HuAb nega

54 A man in his 30s with paraneoplastic cerebellar degeneration and anti-Tr under

55 Here, we present a patient who developed paraneoplastic cerebellar degeneration and anti-Yo antib

56 e anti-Tr immune response is associated with paraneoplastic cerebellar degeneration and Hodgkin lymph

57 rum and cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration associated with c

58 rocessed HLA-A2.1 restricted epitopes of the paraneoplastic cerebellar degeneration breast/ovarian ca

59 at patients with the same tumour can develop paraneoplastic cerebellar degeneration by different immu

60 patients who differed from the HuAb negative paraneoplastic cerebellar degeneration cohort, HuAb posi

61 m of 57 patients with presenting symptoms of paraneoplastic cerebellar degeneration for the presence

62 A total of nine patients (16%) from both paraneoplastic cerebellar degeneration groups developed

63 In patients with small-cell lung cancer, paraneoplastic cerebellar degeneration may occur with or

64 In other disorders, such as paraneoplastic cerebellar degeneration or paraneoplastic

65 erebellar degeneration and 10% HuAb negative paraneoplastic cerebellar degeneration patients (P < 0.0

66 In addition, 20% of HuAb negative paraneoplastic cerebellar degeneration patients without

67 0% of HuAb positive and 20% of HuAb negative paraneoplastic cerebellar degeneration patients, the tum

68 d in the peripheral blood of two HLA-A2.1(+) paraneoplastic cerebellar degeneration patients.

69 era from patients with Hodgkin's disease and paraneoplastic cerebellar degeneration resulted in the i

70 Furthermore, paraneoplastic cerebellar degeneration sometimes occurs

71 bodies associated with different cancers and paraneoplastic cerebellar degeneration suggests that sev

72 Patients with paraneoplastic cerebellar degeneration who were HuAb pos

73 litis, 1 paraneoplastic encephalomyelitis, 1 paraneoplastic cerebellar degeneration, and 1 opsoclonus

74 immunomodulation did not alter the course of paraneoplastic cerebellar degeneration, but improved Lam

75 /or serum samples from 5 other patients with paraneoplastic cerebellar degeneration, HL, and anti-Tr.

76 and immunological developments, focusing on paraneoplastic cerebellar degeneration, opsoclonus-myocl

77 thophysiology were described 10 years ago in paraneoplastic cerebellar degeneration.

78 pecially lung, ovarian and breast, can cause paraneoplastic cerebellar degeneration.

79 Paraneoplastic chorea is described in 16 patients: 11 wi

80 Paraneoplastic cloudy vitelliform submaculopathy, a form

81 motor neuron disease has been reported as a paraneoplastic complication, it has not been previously

82 Melanoma-associated retinopathy (MAR) is a paraneoplastic condition that causes visual symptoms of

83 myoclonus should always raise suspicion of a paraneoplastic condition, but any paraneoplastic syndrom

84 cal disorder in both groups could occur as a paraneoplastic condition.

85 mutant tumors has the potential to provoke a paraneoplastic condition.

86 Paraneoplastic conditions may manifest with eye findings

87 neuropathy occurring idiopathically or in a paraneoplastic context.

88 id decarboxylase antibodies (GAD-abs) in the paraneoplastic context.

89 ambert-Eaton myasthenic syndrome (LEMS) is a paraneoplastic disorder in which autoantibodies apparent

90 ntibodies to Ma1 and Ma2 proteins identify a paraneoplastic disorder that affects the limbic system,

91 y, Monoclonal protein and Skin changes) is a paraneoplastic disorder with a 'demyelinating' periphera

92 and brain-stem dysfunction may result from a paraneoplastic disorder.

93 This case extends the context of NMOSD as a paraneoplastic disorder.

94 omas account for several lung cancer-related paraneoplastic disorders affecting cholinergic systems,

95 Because patients with paraneoplastic disorders affecting vision and eye moveme

96 oimmune-related diseases, which can occur as paraneoplastic disorders and, importantly, have an incre

97 Most neurologic paraneoplastic disorders are thought to be caused by an

98 Certain paraneoplastic disorders associated with degeneration of

99 oantibody profiles observed in patients with paraneoplastic disorders imply the targeting of multiple

100 Paraneoplastic disorders may affect any part of the cent

101 Recently proposed diagnostic criteria for paraneoplastic disorders may assist in determining the l

102 Paraneoplastic disorders of the CNS result from immune r

103 To describe the paraneoplastic disorders of the motor and sensory nerves

104 asing recognition of an extensive variety of paraneoplastic disorders of the peripheral nerves.

105 n important diagnosis to be aware of because paraneoplastic disorders often herald an occult tumor.

106 Such mechanism may be common for other paraneoplastic disorders or autoimmune diseases where an

107 tonomic dysfunction and with neurological or paraneoplastic disorders unrelated to the autonomic nerv

108 ze the clinical manifestations of neurologic paraneoplastic disorders, and to distinguish them from o

109 s the varied clinical spectrum of neurologic paraneoplastic disorders, describes recent advances in o

110 is reminiscent of that seen in neurological paraneoplastic disorders, in which antigens targeted for

111 is, one of the most common manifestations of paraneoplastic disorders, is characterized by rapid onse

112 psychiatric and behavioral manifestations of paraneoplastic disorders, the cellular mechanisms underl

113 ists to be aware of initial presentations of paraneoplastic disorders.

114 ic neuropathies, and motor neuron disease as paraneoplastic disorders.

115 chete, fungal, and retroviral infection; (2) Paraneoplastic disorders; (3) Amphetamine abuse; (4) Gra

116 Paraneoplastic encephalitides usually precede a diagnosi

117 He was diagnosed with paraneoplastic encephalitis and blepharospasm.

118 It is quickly becoming the most common paraneoplastic encephalitis.

119 Paraneoplastic encephalomyelitis developed as the presen

120 Two patients with paraneoplastic encephalomyelitis manifested predominantl

121 oplastic syndromes (5 limbic encephalitis, 1 paraneoplastic encephalomyelitis, 1 paraneoplastic cereb

122 are associated with an anti-tumor effect and paraneoplastic encephalomyelitis, we tested sera from Hu

123 emic leucoencephalopathy, vasculopathies and paraneoplastic encephalopathy.

124 a product of malignant tumors that mediates paraneoplastic hypercalcemia.

125 We identified a new paraneoplastic IgG, PCA-2 (Purkinje cell cytoplasmic ant

126 ms, seizures, and central hypoventilation, a paraneoplastic immune-mediated syndrome should be consid

127 We have defined a new paraneoplastic immunoglobulin G (IgG) autoantibody speci

128 About half of the cases reported have been paraneoplastic in origin, with the majority of tumors re

129 mmune retinopathies as nonparaneoplastic and paraneoplastic, including cancer-associated retinopathy

130 Paraneoplastic limbic encephalitis (PLE) is a rare disor

131 Of 13 patients with testicular cancer and paraneoplastic limbic or brain-stem encephalitis (or bot

132 Paraneoplastic limbic or brain-stem encephalitis occurs

133 sociated encephalitis differs from classical paraneoplastic limbic or brainstem encephalitis, and the

134 d the case of a woman with breast cancer and paraneoplastic lower motor neuron syndrome whose serum c

135 tent with the autoimmune pathogenesis of the paraneoplastic lower motor neuron syndrome.

136 otein 93 and the testicular tumor-associated paraneoplastic Ma antigen (PNMA) and increased expressio

137 o describe rheumatic syndromes that can be a paraneoplastic manifestation of an underlying malignancy

138 bt on the distinction between neoplastic and paraneoplastic mechanisms of neuromuscular manifestation

139 ain include distant tumor effects, involving paraneoplastic mechanisms.

140 and neurons, is a target antigen in a human paraneoplastic motor disorder [paraneoplastic opsoclonus

141 h prevalence, compared with other recognized paraneoplastic neural autoantibodies, justifies its test

142 dies, justifies its testing in comprehensive paraneoplastic neural autoantibody evaluation.

143 Immune responses to paraneoplastic neurologic degeneration antigens, also ca

144 Studies of the disorders known as paraneoplastic neurologic degenerations exemplify the su

145 The paraneoplastic neurologic disorders (PND) are a rare gro

146 Paraneoplastic neurologic disorders (PND) are autoimmune

147 Major advances in the management of paraneoplastic neurologic disorders (PND) include the de

148 Paraneoplastic neurologic disorders (PNDs) are believed

149 Paraneoplastic neurologic disorders (PNDs) offer an unco

150 The paraneoplastic neurologic disorders target several famil

151 to serve as tumor rejection antigens in the paraneoplastic neurologic disorders.

152 n a subset of patients, triggering of the Hu paraneoplastic neurologic syndrome.

153 cuss the evidence for this from the field of paraneoplastic neurologic syndromes and the discovery of

154 Recent progress in the understanding of the paraneoplastic neurologic syndromes has included further

155 cesses, causing neurodegenerative disorders (paraneoplastic neurologic syndromes).

156 ity against an undetected solid neoplasm and paraneoplastic neurological (PCA-1) autoimmunity.

157 i-Hu) specificity is a serological marker of paraneoplastic neurological autoimmunity (including ente

158 ntibodies (ANNA-1 and ANNA-2) are markers of paraneoplastic neurological autoimmunity related to smal

159 disorder and evidence for its pertinence to paraneoplastic neurological autoimmunity.

160 The paraneoplastic neurological degenerations (PNDs) are rem

161 tacrolimus therapy may benefit patients with paraneoplastic neurological disease and other T cell-med

162 oantibody found in a subset of patients with paraneoplastic neurological disease.

163 occult tumour in a patient with a suspected paraneoplastic neurological disorder (PND) may be diffic

164 araneoplastic autoimmunity in a child, and a paraneoplastic neurological disorder in the context of D

165 -2 autoantigen, represents a novel target in paraneoplastic neurological disorders and has high predi

166 antibodies has facilitated the diagnosis of paraneoplastic neurological disorders and the early dete

167 onal antibodies in the sera of patients with paraneoplastic neurological disorders and to clone the c

168 Paraneoplastic neurological disorders are rare condition

169 r study demonstrates that some patients with paraneoplastic neurological disorders develop antibodies

170 Paraneoplastic neurological disorders may result from au

171 The paraneoplastic neurological disorders provide perhaps th

172 es of 1705 sera from patients with suspected paraneoplastic neurological disorders resulted in the id

173 mal individuals, 179 cancer patients without paraneoplastic neurological symptoms, 96 patients with p

174 Paraneoplastic neurological syndromes (PNSs) rarely asso

175 Paraneoplastic neurological syndromes cause severe neuro

176 Although paraneoplastic neurological syndromes have been associat

177 approximately 68,000 patients with suspected paraneoplastic neurological syndromes.

178 n the spinal fluid of three individuals with paraneoplastic neurological syndromes.

179 a neurological presentation and one or more paraneoplastic neuronal nuclear or cytoplasmic autoantib

180 Paraneoplastic neuronopathies are presumed to be the res

181 mmunoglobulin M paraproteinaemic neuropathy, paraneoplastic neuropathy and the neuropathy associated

182 In summary, CRMP-5-IgG defines a paraneoplastic ophthalmological entity of combined optic

183 Paraneoplastic opsoclonus myoclonus ataxia (POMA) is a n

184 ding protein that is an autoimmune target in paraneoplastic opsoclonus myoclonus ataxia (POMA) patien

185 Nova-1, an autoantigen in paraneoplastic opsoclonus myoclonus ataxia (POMA), a dis

186 ins are neuron-specific antigens targeted in paraneoplastic opsoclonus myoclonus ataxia (POMA), an au

187 In patients suffering from paraneoplastic opsoclonus myoclonus ataxia (POMA), Nova-

188 These findings uncover a novel phenotype of paraneoplastic opsoclonus that until recently was likely

189 some circumstances and its association with paraneoplastic opsoclonus, myoclonus, and ataxia.

190 ction of the RNA-binding protein Nova-1, the paraneoplastic opsoclonus-myoclonus ataxia (POMA) antige

191 cancer patients with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia (POMA).

192 en in a human paraneoplastic motor disorder [paraneoplastic opsoclonus-myoclonus ataxia (POMA)].

193 e target antigens in the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia and contain K

194 ted in patients with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia, which is cha

195 tigens are implicated in the pathogenesis of paraneoplastic opsoclonus-myoclonus-ataxia (POMA).

196 1 patients with encephalitis suspected to be paraneoplastic or immune mediated and 13 individuals wit

197 15 patients who were suspected to have paraneoplastic or immune-mediated limbic encephalitis we

198 aled a new category of disorders that can be paraneoplastic or not, and associate with antibodies aga

199 mporal lobes than in patients with classical paraneoplastic or VGKC antibodies.

200 generation caused by hereditary, idiopathic, paraneoplastic, or postinfectious pancerebellitis.

201 Detection of these antibodies supports the paraneoplastic origin of the neurologic disorder and cou

202 In a subset of cases, SMS has an autoimmune paraneoplastic origin.

203 However, his paraneoplastic panel was positive for anti-Hu antibodies

204 ys) administration of immunotherapies in non-paraneoplastic patients (P < 0.0001) and earlier tumour

205 s (P < 0.0001) and earlier tumour removal in paraneoplastic patients (P = 0.02).

206 for potentially pathogenic antibodies in non-paraneoplastic patients with cerebellar ataxia.

207 e not detected in sera from 24 patients with paraneoplastic pemphigus (including 10 with concomitant

208 Sera of patients with paraneoplastic pemphigus (PNP) characteristically immuno

209 Paraneoplastic pemphigus has been associated with both m

210 onal HHV8-associated diseases, patients with paraneoplastic pemphigus, as well as patients with pemph

211 cy-associated autoimmune blistering disease, paraneoplastic pemphigus.

212 nomic rearrangements possibly underlying the paraneoplastic pemphigus.

213 bullous pemphigoid; and 1 suspected case of paraneoplastic pemphigus.

214 leted to date, and discusses the interesting paraneoplastic phenomena associated with thymomas.

215 nts with pancreatic cancer is likely to be a paraneoplastic phenomenon caused by tumor-secreted produ

216 and temporal association with SCT and (2) a paraneoplastic phenomenon, supported by frequent early m

217 vitelliform lesions found in acute exudative paraneoplastic polymorphous vitelliform maculopathy, alt

218 a relatively common form of autoimmune, non-paraneoplastic, potentially treatable encephalitis that

219 ECENT FINDINGS: This is an updated review of paraneoplastic presentations of synovitis, bone disease,

220 d the diagnosis of lymphoma, suggestive of a paraneoplastic process.

221 utaminase and antiendomysial antibodies, and paraneoplastic profile.

222 The paraneoplastic PTHrP has also been implicated in tumor p

223 Paraneoplastic retinopathy and autosomal recessive bestr

224 Paraneoplastic retinopathy is caused by the cross-reacti

225 oplastic vitelliform retinopathy, a presumed paraneoplastic retinopathy with features of atypical mel

226 ble, with more favorable results achieved in paraneoplastic retinopathy, particularly cancer-associat

227 Although paraneoplastic rheumatic syndromes are rare, clinicians

228 The pathogenesis of paraneoplastic rheumatologic diseases is complex and not

229 urine pro-B cells, suggesting that they have paraneoplastic roles in leukemias that express E2A-HLF,

230 a and explore a model for the development of paraneoplastic scleroderma.

231 antibodies are frequently associated with a paraneoplastic sensorimotor axonal neuropathy and small-

232 Of this group of disorders, paraneoplastic sensory neuronopathies are the most frequ

233 as paraneoplastic cerebellar degeneration or paraneoplastic sensory neuronopathy, neither removal of

234 Paraneoplastic serological and cerebrospinal fluid evalu

235 Paraneoplastic SPS is commonly associated with antiamphi

236 n (amphiphysin I), a dominant autoantigen in paraneoplastic Stiff-man syndrome, is a neuronal protein

237 Amphiphysin, a major autoantigen in paraneoplastic Stiff-Man syndrome, is an SH3 domain-cont

238 Some disorders are paraneoplastic, such as anti-CRMP5-associated chorea, an

239 109 small-cell lung cancer patients without paraneoplastic symptoms had high titres of HuAb.

240 % of small-cell lung cancer patients without paraneoplastic symptoms had these antibodies.

241 some small-cell lung cancer patients without paraneoplastic symptoms.

242 ytotoxic CD8+ T cell in patients with the Hu paraneoplastic syndrome and suggest that SCLC may evade

243 93 individual patients suspected of having a paraneoplastic syndrome and who underwent (18)F-FDG PET

244 93 individual patients suspected of having a paraneoplastic syndrome and who underwent (18)F-FDG PET

245 Melanoma-associated retinopathy (MAR) is a paraneoplastic syndrome associated with cutaneous malign

246 icion of a paraneoplastic condition, but any paraneoplastic syndrome can also occur in patients witho

247 ntagonist (VEGF-TRAP(R1R2)), thus defining a paraneoplastic syndrome caused by excessive VEGF activit

248 resistant, upbeat nystagmus resulting from a paraneoplastic syndrome caused by stage 2A, grade I, nod

249 on the possibility that scleroderma may be a paraneoplastic syndrome in a subset of patients.

250 on that their symptoms or findings reflect a paraneoplastic syndrome may allow the tumor responsible

251 toantibodies or inflammatory gene mutations, paraneoplastic syndrome mechanisms via ectopic cytokine

252 POEMS syndrome is a paraneoplastic syndrome whose acronym stands for less th

253 Limbic encephalitis is typically a paraneoplastic syndrome with a poor prognosis; thus, ide

254 melanocytic proliferation (BDUMP) is a rare paraneoplastic syndrome with characteristic findings, in

255 osition, after acute infection, as part of a paraneoplastic syndrome, and after exposure to neurotoxi

256 (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrome.

257 (18)F-FDG PET/CT in patients with suspected paraneoplastic syndrome.

258 malignancy in patients suspected of having a paraneoplastic syndrome.

259 n of the nervous system may be involved in a paraneoplastic syndrome.

260 malignancy in patients suspected of having a paraneoplastic syndrome.

261 15 patients with cancer presented as classic paraneoplastic syndromes (5 limbic encephalitis, 1 paran

262 Paraneoplastic syndromes (i.e. organ/tissue disorders as

263 Paraneoplastic syndromes affecting the nervous system ar

264 stic neurological symptoms, 96 patients with paraneoplastic syndromes and 10 patients with non-cancer

265 nd toxic molecules to the internodal axon in paraneoplastic syndromes and demyelinating diseases.

266 "brain-testis-cancer" gene related to other paraneoplastic syndromes and tumors.

267 Paraneoplastic syndromes are not frequently associated w

268 of this review is to define and describe the paraneoplastic syndromes associated with gynecologic neo

269 Some paraneoplastic syndromes can be used as marker of progre

270 Twenty-four paraneoplastic syndromes have been associated with gynec

271 Early diagnosis of paraneoplastic syndromes maximizes the likelihood of a f

272 Paraneoplastic syndromes occurring before a cancer diagn

273 eration in normal tissues contributes to the paraneoplastic syndromes of cachexia and anemia.

274 109 small-cell lung cancer patients without paraneoplastic syndromes of the CNS.

275 Most nervous system paraneoplastic syndromes probably result from an immune

276 abnormalities is wide, and include cutaneous paraneoplastic syndromes such as xanthomas, acanthosis n

277 ple sclerosis, neuromyelitis optica, and the paraneoplastic syndromes where highly specific T cell re

278 Recent work has described paraneoplastic syndromes with prominent, and sometimes i

279 rapeutic interventions for a group of visual paraneoplastic syndromes, including carcinoma-associated

280 This tumor is associated with unique paraneoplastic syndromes, such as myasthenia gravis, hyp

281 elevant pathways that lead to the associated paraneoplastic syndromes.

282 oplasm in patients presenting with suspected paraneoplastic syndromes.

283 cally suspected neurologic and nonneurologic paraneoplastic syndromes.

284 ntly fatal malignancy and for the associated paraneoplastic syndromes.

285 We speculate that countering paraneoplastic thrombocytosis either directly or indirec

286 The mechanisms of paraneoplastic thrombocytosis in ovarian cancer and the

287 Paraneoplastic thrombocytosis is associated with many so

288 cytokines in tumor and host tissue leads to paraneoplastic thrombocytosis, which fuels tumor growth.

289 interleukin-6 was an underlying mechanism of paraneoplastic thrombocytosis.

290 used to explore the underlying mechanisms of paraneoplastic thrombocytosis.

291 e spot syndromes and autoimmune, hereditary, paraneoplastic, toxic, and other inflammatory retinopath

292 s to GluR1/2 associate with LE that is often paraneoplastic, treatment responsive, and has a tendency

293 Autoantibodies have defined two paraneoplastic visual disorders related to small-cell lu

294 ructure and its autoantibody localization of paraneoplastic vitelliform retinopathy are still indefin

295 Paraneoplastic vitelliform retinopathy, a presumed paran

296 ar dendritic tips in a melanoma patient with paraneoplastic vitelliform retinopathy.

297 inner nuclear and outer plexiform layers in paraneoplastic vitelliform retinopathy.

298 metastatic cutaneous melanoma, who developed paraneoplastic vitelliform retinopathy.

299 Subgroups were classified as paraneoplastic vs nonparaneoplastic disorders; neuronal